MURAL - Maynooth University Research Archive Library

    Human macrophage migration inhibitory factor potentiates mesenchymal stromal cell efficacy in a clinically relevant model of allergic asthma

    Hawthorne, Ian J. and Dunbar, Hazel and Tunstead, Courteney and Schorpp, Tamara and Weiss, Daniel J. and Enes, Sara Rolandsson and dos Santos, Claudia C. and Armstrong, Michelle E. and Donnelly, Seamas C. and English, Karen (2023) Human macrophage migration inhibitory factor potentiates mesenchymal stromal cell efficacy in a clinically relevant model of allergic asthma. Molecular Therapy. pp. 1-44. ISSN 1525-0016

    Download (7MB) | Preview

    Share your research

    Twitter Facebook LinkedIn GooglePlus Email more...

    Add this article to your Mendeley library


    Current asthma therapies focus on reducing symptoms but fail to restore existing structural damage. Mesenchymal stromal cell (MSC) administration can ameliorate airway inflammation and reverse airway remodelling. However, differences in patient disease microenvironments seem to influence MSC therapeutic effects. Polymorphic CATT tetranucleotide repeat at position 794 of the human macrophage migration inhibitory factor (hMIF) gene has been associated with increased susceptibility and severity of asthma. We investigated the efficacy of human MSCs in high vs low hMIF environments and the impact of MIF pre-licensing of MSCs using humanised MIF mice in a clinically relevant house dust mite (HDM) model of allergic asthma. MSCs significantly attenuated airway inflammation and airway remodelling in high MIF expressing CATT7 mice, but not in CATT5 or wildtype littermates. Differences in efficacy correlated with increased MSC retention in the lungs of CATT7 mice. MIF licensing potentiated MSC anti-inflammatory effects at a previously ineffective dose. Mechanistically, MIF binding to CD74 expressed on MSCs leads to upregulation of COX-2 expression. Blockade of CD74 or COX-2 function in MSCs prior to administration attenuated the efficacy of MIF-licensed MSCs in vivo. These findings suggest that MSC administration may be more efficacious in severe asthma patients with high MIF genotypes (CATT6/7/8).

    Item Type: Article
    Keywords: Human; macrophage; migration inhibitory; potentiates; mesenchymal; stromal cell efficacy; allergic asthma;
    Academic Unit: Faculty of Science and Engineering > Biology
    Faculty of Science and Engineering > Research Institutes > Human Health Institute
    Item ID: 17596
    Identification Number:
    Depositing User: Karen English
    Date Deposited: 25 Sep 2023 12:03
    Journal or Publication Title: Molecular Therapy
    Publisher: Cell Press
    Refereed: Yes
    Use Licence: This item is available under a Creative Commons Attribution Non Commercial Share Alike Licence (CC BY-NC-SA). Details of this licence are available here

    Repository Staff Only(login required)

    View Item Item control page


    Downloads per month over past year

    Origin of downloads